New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals, and Trevena — Factors of Influence, Major Initiatives and Sustained Production

NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of OFG Bancorp (NYSE:OFG), Oshkosh Corporation (NYSE:OSK), Vishay Precision Group, Inc. (NYSE:VPG), Endocyte, Inc. (NASDAQ:ECYT), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Trevena, Inc. (NASDAQ:TRVN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

OFG DOWNLOAD: http://Fundamental-Markets.com/register/?so=OFG
OSK DOWNLOAD: http://Fundamental-Markets.com/register/?so=OSK
VPG DOWNLOAD: http://Fundamental-Markets.com/register/?so=VPG
ECYT DOWNLOAD: http://Fundamental-Markets.com/register/?so=ECYT
BCRX DOWNLOAD: http://Fundamental-Markets.com/register/?so=BCRX
TRVN DOWNLOAD: http://Fundamental-Markets.com/register/?so=TRVN

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine OFG Bancorp (NYSE:OFG), Oshkosh Corporation (NYSE:OSK), Vishay Precision Group, Inc. (NYSE:VPG), Endocyte, Inc. (NASDAQ:ECYT), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and Trevena, Inc. (NASDAQ:TRVN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed April 24th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

OFG BANCORP (OFG) REPORT OVERVIEW

OFG's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, OFG reported interest income of $83.17MM vs $86.79MM (down 4.17%) and basic earnings per share $0.31 vs $0.27 (up 14.81%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, OFG reported interest income of $345.65MM vs $356.59MM (down 3.07%) and basic earnings per share $0.88 vs $1.03 (down 14.56%). OFG is expected to report earnings on July 20th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.30. The estimated EPS forecast for the next fiscal year is $1.29 and is expected to report on January 29th, 2019.

To read the full OFG Bancorp (OFG) report, download it here: http://Fundamental-Markets.com/register/?so=OFG

-----------------------------------------

OSHKOSH CORPORATION (OSK) REPORT OVERVIEW

Oshkosh's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Oshkosh reported revenue of $1,586.30MM vs $1,211.40MM (up 30.95%) and basic earnings per share $0.75 vs $0.26 (up 188.46%). For the twelve months ended September 30th, 2017 vs September 30th, 2016, Oshkosh reported revenue of $6,829.60MM vs $6,279.20MM (up 8.77%) and basic earnings per share $3.82 vs $2.94 (up 29.93%). Oshkosh is expected to report earnings on April 26th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.76. The estimated EPS forecast for the next fiscal year is $6.09 and is expected to report on October 30th, 2018.

To read the full Oshkosh Corporation (OSK) report, download it here: http://Fundamental-Markets.com/register/?so=OSK

-----------------------------------------

VISHAY PRECISION GROUP, INC. (VPG) REPORT OVERVIEW

Vishay Precision Group's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Vishay Precision Group reported revenue of $69.44MM vs $55.81MM (up 24.41%) and basic earnings per share $0.34 vs $0.23 (up 47.83%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Vishay Precision Group reported revenue of $254.35MM vs $224.93MM (up 13.08%) and basic earnings per share $1.08 vs $0.49 (up 120.41%). Vishay Precision Group is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.19. The estimated EPS forecast for the next fiscal year is $1.60 and is expected to report on February 20th, 2019.

To read the full Vishay Precision Group, Inc. (VPG) report, download it here: http://Fundamental-Markets.com/register/?so=VPG

-----------------------------------------

ENDOCYTE, INC. (ECYT) REPORT OVERVIEW

Endocyte's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Endocyte reported revenue of $0.01MM vs $0.01MM (unchanged) and basic earnings per share -$0.15 vs -$0.26. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Endocyte reported revenue of $0.07MM vs $0.07MM (unchanged) and basic earnings per share -$1.25 vs -$1.04. Endocyte is expected to report earnings on May 9th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.27. The estimated EPS forecast for the next fiscal year is -$0.80 and is expected to report on February 25th, 2019.

To read the full Endocyte, Inc. (ECYT) report, download it here: http://Fundamental-Markets.com/register/?so=ECYT

-----------------------------------------

BIOCRYST PHARMACEUTICALS, INC. (BCRX) REPORT OVERVIEW

BioCryst Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, BioCryst Pharmaceuticals reported revenue of $3.89MM vs $8.98MM (down 56.70%) and basic earnings per share -$0.20 vs -$0.06. For the twelve months ended December 31st, 2017 vs December 31st, 2016, BioCryst Pharmaceuticals reported revenue of $25.19MM vs $26.35MM (down 4.43%) and basic earnings per share -$0.78 vs -$0.75. BioCryst Pharmaceuticals is expected to report earnings on May 3rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.19. The estimated EPS forecast for the next fiscal year is -$0.78 and is expected to report on February 26th, 2019.

To read the full BioCryst Pharmaceuticals, Inc. (BCRX) report, download it here: http://Fundamental-Markets.com/register/?so=BCRX

-----------------------------------------

TREVENA, INC. (TRVN) REPORT OVERVIEW

Trevena's Recent Financial Performance

Trevena is expected to report earnings on May 3rd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was -$0.36. The estimated EPS forecast for the next fiscal year is -$0.70 and is expected to report on March 6th, 2019.

To read the full Trevena, Inc. (TRVN) report, download it here: http://Fundamental-Markets.com/register/?so=TRVN

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected].

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected].

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.